|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
Fort Mills Times Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
The Age |
How DIY antibodies changed my life
The Age The first Australian to treat immune system deficiency by self-administering concentrated antibodies has given the process the thumbs up. Waramanga’s Julie Cornwell-Kelly has made history by injecting a highly concentrated subcutaneous immunoglobulin … |
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
Business Wire (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
|
Research and Markets: Therapy Class Overview : Rituximab Biosimilar …
4-traders (press release) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several … |
|
Monoclonal Antibodies Market for Breast Cancer to More than Double by 2019
PR Carbon (press release) FOR IMMEDIATE RELEASE, Illinois – United States – November 06, 2013 (PR Carbon): The market value for monoclonal antibodies (mAbs) in breast cancer treatment will experience a massive increase from $4.8 billion in 2012 to $10.9 billion in 2019, … |
|
How DIY antibodies changed my life
The Canberra Times The first Australian to treat immune system deficiency by self-administering concentrated antibodies has given the process the thumbs up. Waramanga’s Julie Cornwell-Kelly has made history by injecting a highly concentrated subcutaneous immunoglobulin … |
|
ADC Therapeutics, Five Prime sign exclusive license agreement for human …
News-Medical.net Under the agreement, ADC Therapeutics plans to initiate preclinical research and development of antibody-drug conjugates using the antibodies licensed from Five Prime immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs. Five Prime licensing deal propels it into hot antibody-drug conjugate spaceSan Francisco Business Times (blog) |
Refinery29 |
One Dose of HPV Vaccine Could Be Enough
WBUR Researchers found HPV antibodies in the blood of Costa Rican women who had received one dose of an HPV vaccine four years prior, indicating that one shot might be enough to equip the immune system to recognize and fight HPV infection. While antibody … One Dose of HPV Vaccine May Be EnoughDrug Discovery & Development New research suggests one dose of HPV vaccine may be enough to prevent …Science Recorder Single Dose of HPV Vaccine May Be Enough to Guard Against Cervical CancerU.S. News & World Report Orlando Sentinel (blog) –Huffington Post all 105 news articles » |
|
Potential Utility of Rituximab for Graves’ Orbitopathy
Journal of Clinical Endocrinology and Metabolism Address all correspondence and requests for reprints to: Mario Salvi, MD, Graves’ Orbitopathy Unit, Fondazione Cà Granda, Istituto di Ricovero e Cura a Carattere Scientifico, Department of Clinical and Community Sciences, University of Milan, Via … |
Refinery29 |
One Dose of HPV Vaccine Induces Long-Term Antibodies
Monthly Prescribing Reference (HealthDay News) – Women who receive only one dose of a human papillomavirus (HPV) vaccine have readily detectable antibody levels that remain stable for four years, according to a study published in the November issue of Cancer Prevention Research. One Dose of HPV Vaccine May Be Enough, Study FindsRH Reality Check One Dose of HPV Vaccine May Be Enough to Prevent Cervical CancerAlaska Native News 1 Dose of HPV Vaccine May Provide Lasting ProtectionWSAW New Straits Times –Medical Daily –Science Recorder all 104 news articles » |